Search results for "Anus"

showing 10 items of 841 documents

Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vacc…

2003

Safety, reactogenicity and immunogenicity of GSK Biologicals` hexavalent DTPa-HBV-IPV/Hib vaccine (Infanrix(R)hexa) was assessed when used for primary vaccination at 3, 4 and 5 months of age (N = 2163), compared to the separate administration of DTPa-IPV/Hib and HBV vaccines (N = 720). A similar safety and reactogenicity profile was demonstrated for both vaccine regimens, as well as a good immune response for all antigen components. By offering protection against six diseases in it series of single injections, the hexavalent DTPa-HBV-IPV/Hib vaccine was shown to be a safe, well tolerated and immunogenic alternative to primary immunization with licensed separately administered vaccines. (C) …

MaleHaemophilus InfectionsDiphtheria ToxoidWhooping Coughmedicine.disease_causecomplex mixturesHaemophilus influenzaeConjugate vaccinemedicineTetanus ToxoidHumansHepatitis B VaccinesVaccines CombinedBacterial CapsulesDiphtheria-Tetanus-Pertussis VaccineHaemophilus VaccinesPertussis VaccineReactogenicityTetanusGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityDiphtheriaPolysaccharides BacterialVaccinationPublic Health Environmental and Occupational HealthInfantDiphtheriamedicine.diseaseHepatitis BVirologyPoliovirus Vaccine InactivatedInfectious DiseasesHib vaccineImmunizationImmunologyInactivated Poliovirus VaccineMolecular MedicineFemalebusinessPoliomyelitisVaccine
researchProduct

Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant…

1998

With an increasing number of new vaccines available for routine childhood immunization, combination vaccines are needed in order to maintain or achieve a high compliance with recommended immunization programmes. In a prospective, randomized, comparative, multi-centre study, 822 healthy infants were enrolled to receive three doses of either a candidate or a commercially available Haemophilus influenzae type b (Hib) vaccine concomitantly with diphtheria-, tetanus- acellular pertussis (DTaP) vaccine. Study subjects were randomly allocated to one of the following groups: (1) separate, or (2) mixed injection of DTaP and candidate Hib vaccine, or (3) separate injection of DTaP and commercial Hib …

MaleHaemophilus InfectionsWhooping CoughImmunization SecondaryEnzyme-Linked Immunosorbent AssayBooster doseDiphtheria-Tetanus-acellular Pertussis Vaccinescomplex mixturesTetanus ToxoidmedicineHumansProspective StudiesDiphtheria-Tetanus-Pertussis VaccineDiphtheria-Tetanus-acellular Pertussis VaccinesWhooping coughHaemophilus VaccinesAnalysis of VarianceChi-Square DistributionTetanusVaccines ConjugateReactogenicityTetanusbusiness.industryDiphtheriaToxoidInfantDiphtheriamedicine.diseaseAntibodies BacterialHib vaccinePediatrics Perinatology and Child HealthImmunologyFemalebusinessEuropean Journal of Pediatrics
researchProduct

Maintaining everyday life praxis in the time of COVID-19 pandemic measures (ELP-COVID-19 survey)

2020

Abstract Background The extreme social circumstances caused by declared COVID-19 pandemic deeply intervene people’s everyday life and should not be neglected but seen through the view of social reality pinpointing the ‘ordinary’ people. In this article, authors explored basic segments of everyday and their subjective perception to what extent sleeping habits, physical inactivity, physical activity, nutritional habits and smoking have changed. Methods The online survey was conducted in nine European countries (Bosnia and Herzegovina, Croatia, Greece, Kosovo*, Italy, Serbia, Slovakia, Slovenia and Spain) in 4108 participants, aged 15–82 years. The survey took place 30–40 days after World Heal…

MaleHealth Behaviordaily life praxispandemijephysical activitygibanje0302 clinical medicinePandemic030212 general & internal medicineYoung adultEveryday lifemedia_commonAged 80 and overživljenjski stilPublic healtheducation.field_of_studyPraxisudc:316.728:616-036.21SmokingCOVID-19 pandemic measurespublic healthsleeping habitsMiddle AgedEuropeAdolescent Adult Aged 80 and over COVID-19 Europe Exercise Feeding Behavior Female Humans Male Middle Aged Pandemics SARS-CoV-2 Screen Time Sleep Smoking Young Adult Health Behavior Life StyleFemalePsychologyAcademicSubjects/SOC02610AdultCoronavirus disease 2019 (COVID-19)Adolescentmedia_common.quotation_subjectPopulationspalne navadeOriginal Manuscriptphysical activity ; smoking ; lack of exercise ; alcohol drinking ; sports ; World Health Organization ; eating ; sleep ; pandemics ; screen time ; containment ; healthy lifestyle ; coronavirus pandemicScreen Time03 medical and health sciencesScreen timeYoung AdultSleeping habitsHumansAcademicSubjects/MED00860AcademicSubjects/SOC01210educationExerciseLife StylePandemicscoronavirus pandemicAgedConsumption (economics)Daily life praxisPhysical activitySARS-CoV-2koronavirusjavno zdravjePublic Health Environmental and Occupational HealthEating habitsCOVID-19eating habitsFeeding BehaviorCOVID-19 ukrepiprehranjevalne navadeSleepgibalna aktivnost030217 neurology & neurosurgeryDemography
researchProduct

Cardiovascular events and intensity of treatment in polycythemia vera.

2013

A b s t r ac t Background Current treatment recommendations for patients with polycythemia vera call for maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested in a randomized clinical trial. Methods We randomly assigned 365 adults with JAK2-positive polycythemia vera who were being treated with phlebotomy, hydroxyurea, or both to receive either more intensive treatment (target hematocrit, <45%) (low-hematocrit group) or less intensive treatment (target hematocrit, 45 to 50%) (high-hematocrit group). The primary composite end point was the time until death from cardiovascular causes or major thrombotic events. The secondary end points were cardiovascula…

MaleHematocritRECURRENT THROMBOSISlaw.inventionAged; Antineoplastic Agents; Cardiovascular Diseases; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hydroxyurea; Janus Kinase 2; Male; Middle Aged; Polycythemia Vera; Thrombosis; Hematocrit; Phlebotomy; Medicine (all)LEUKOCYTOSISPolycythemia veraRandomized controlled trialPhlebotomylawhemic and lymphatic diseasesESSENTIAL THROMBOCYTHEMIAClinical endpointHydroxyureaPolycythemia Vera Secondary ProphylaxisESSENTIAL THROMBOCYTHEMIA RECURRENT THROMBOSIS RISK-FACTOR HEMATOCRIT MANAGEMENT LEUKOCYTOSIS PREVENTION DIAGNOSIS EFFICACY WARFARINPolycythemia Veramedicine.diagnostic_testMedicine (all)Hazard ratioGeneral MedicineMiddle AgedCombined Modality TherapyHematocritCardiovascular DiseasesFemalemedicine.medical_specialtyrandomized trial; polycythemia veraAntineoplastic AgentsCardiovascular eventDIAGNOSISWARFARINRISK-FACTORInternal medicineMANAGEMENTmedicineHumansMyelofibrosisAdverse effectAgedbusiness.industryThrombosisPhlebotomyJanus Kinase 2EFFICACYmedicine.diseasePREVENTIONSurgeryPolycythemia Vera Cardiovascular event hematocritSettore MED/15 - MALATTIE DEL SANGUEbusinessFollow-Up Studies
researchProduct

Cellular immune response of a varicella vaccine following simultaneous DTaP and VZV vaccination.

1999

Abstract Background : Chickenpox and zoster are an important cause of morbidity among children and adults. The ability of a new, thermostable vaccine to induce varicella–zoster-virus (VZV)-specific humoral and cell mediated immunity when given simultaneously with diphtheria–tetanus-acellular pertussis vaccine (DTaP) as a booster dose in the second year of life was investigated. Methods : A new, temperature stable varicella vaccine (OKA-strain, SB-Biologicals, Rixensart, Belgium) was given simultaneously with a booster dose of DTaP vaccine. VZV-specific humoral and cell-mediated immunity was studied in the first 27 out of 232 vaccinated children at 16–28 months of age, from blood samples dra…

MaleHerpesvirus 3 HumanVaricella vaccinevirusesT-LymphocytesImmunization SecondaryBooster dosemedicine.disease_causeAntibodies ViralLymphocyte ActivationChickenpox VaccineInterferon-gammamedicineHumansWhooping coughDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleImmunity CellularChickenpoxintegumentary systemGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryTetanusPublic Health Environmental and Occupational HealthVaricella zoster virusvirus diseasesInfantmedicine.diseaseVirologyInterleukin-10VaccinationInfectious DiseasesChild PreschoolImmunoglobulin GImmunologyMolecular MedicinePertussis vaccineFemalebusinessmedicine.drugVaccine
researchProduct

Two versus three doses of a meningococcal C conjugate vaccine concomitantly administered with a hexavalent DTaP-IPV-HBV/Hib vaccine in healthy infant…

2007

The immunogenicity and reactogenicity of a meningococcal serogroup C (MenC) conjugate vaccine given concomitantly with DTaP-IPV-HBV/Hib vaccine according to a two- or three-dose schedule in healthy infants was evaluated. At 1 month post-vaccination, 98% (two doses) and 100% (three doses) of subjects had serum bactericidal antibody using human complement assay (hSBA) titres > or =1:8; at 12 months of age > or =89% of subjects in each group remained seroprotected. Induction of immunological memory, as evaluated by administration of a meningococcal serogroup A/C polysaccharide vaccine challenge dose, was similar for both regimens and no interference was observed in the immune response to MenC …

MaleImmunization SecondaryMeningococcal VaccinesMeningococcal vaccineMeningitis Meningococcalmedicine.disease_causeMeningococcal diseaseConjugate vaccinemedicineHumansHepatitis B VaccinesVaccines CombinedHepatitis B AntibodiesBacterial CapsulesDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleHaemophilus VaccinesHepatitis B virusReactogenicityMicrobial ViabilityVaccines ConjugateGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityNeisseria meningitidisPublic Health Environmental and Occupational HealthInfantmedicine.diseaseVirologyAntibodies BacterialPoliovirus Vaccine InactivatedInfectious DiseasesHib vaccineImmunologyMolecular MedicineFemalebusinessImmunologic MemoryVaccine
researchProduct

Anal cancer: ESMO–ESSO–ESTRO clinical practice guidelines for diagnosis, treatment and follow-up

2014

Squamous cell carcinoma of the anus (SCCA) is a rare cancer but its incidence is increasing throughout the world, and is particularly high in the human immunodeficiency virus positive (HIVþ) population. A multidisciplinary approach is mandatory (involving radiation therapists, medical oncologists, surgeons, radiologists and pathologists). SCCA usually spreads in a loco-regional manner within and outside the anal canal. Lymph node involvement at diagnosis is observed in 30%e40% of cases while systemic spread is uncommon with distant extrapelvic metastases recorded in 5%e8% at onset, and rates of metastatic progression after primary treatment between 10 and 20%. SCCA is strongly associated wi…

MaleMESH: Combined Modality TherapyAnal Carcinomamedicine.medical_treatmentMESH: Lymphatic MetastasisMedical OncologyMESH: Anus Neoplasms0302 clinical medicineDiagnosisSocieties MedicalMESH: Medical Oncologyeducation.field_of_studyIncidence (epidemiology)Follow-upAnal MarginMESH: Carcinoma Squamous CellGeneral MedicineHematologyMESH: Follow-Up StudiesAnal canalAnus NeoplasmsPrognosisCombined Modality Therapy3. Good healthmedicine.anatomical_structureOncologyRadiology Nuclear Medicine and imaging030220 oncology & carcinogenesisLymphatic MetastasisCarcinoma Squamous Cell030211 gastroenterology & hepatologyFemaleRadiologymedicine.medical_specialtyHealth Planning GuidelinesPopulationMESH: Societies MedicalRectumGuidelinesMESH: Prognosis03 medical and health sciencesmedicineAnal cancerHumansRadiology Nuclear Medicine and imagingeducationNeoplasm StagingMESH: Humansbusiness.industryCancerAnusmedicine.diseaseMESH: MaleSurgeryRadiation therapyTreatmentSurgery[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieAnal cancerbusinessMESH: FemaleFollow-Up Studies
researchProduct

Constitutive activation of JAK2 in mammary epithelium elevates Stat5 signalling, promotes alveologenesis and resistance to cell death, and contribute…

2011

Signalling through the janus kinase (JAK)/signal transducer and activator of transcription (Stat) pathway is required at different stages of mammary gland development, and this pathway is frequently hyper-activated in cancer, including tumours of the breast. Stats 3, 5 and 6 have important roles in the differentiation and survival of mammary alveolar cells, but somewhat paradoxically, both Stat3 and 5 can have oncogenic activity in the mammary gland. Constitutive activation of JAK2 could be anticipated to result in hyper-activation of Stats 1, 3, 5 and 6 with concomitant cell transformation, although the outcome is difficult to envisage, particularly since Stats 3 and 5 play opposing roles …

MaleMammary glandTransplantation HeterologousMutation MissenseMice NudeBreast NeoplasmsMammary Neoplasms AnimalMiceMammary Glands AnimalPregnancyhemic and lymphatic diseasesCell Line TumormedicineSTAT5 Transcription FactorAnimalsHumansLactationSTAT3Mammary Glands HumanMolecular BiologySTAT5Mice KnockoutOriginal PaperJanus kinase 2biologyCell DeathCell growthCell BiologyJanus Kinase 2Enzyme Activationmedicine.anatomical_structureCell Transformation Neoplasticbiology.proteinSTAT proteinCancer researchFemaleSignal transductionJanus kinaseNeoplasm TransplantationSignal Transduction
researchProduct

Evaluation of the immunogenicity and reactogenicity of a DTPa-HBV-IPV combination vaccine Co-administered with a hib conjugate vaccine either as a si…

2004

A combined DTPa-HBV-IPV/Hib vaccine containing diphtheria (D), tetanus (T), acellular pertussis (Pa), hepatitis B (HBV) and types 1, 2 and 3 inactivated polioviruses (IPV) extemporaneously mixed with a conjugated Haemophilus influenzae type b (Hib) vaccine (Group 1) was compared to the DTPa-HBV-IPV and Hib vaccines (Group 2) administered separately at 3, 5 and 11 months of age (n = 440). A microneutralization assay was used to detect antibodies against the 3 polio virus types (cut-off 1:8 dil), RIA for anti-HBs antibodies (cut-off 10 mIU/ml) and ELISA for antibodies against all other vaccine antigens (cut-off: 0.1 IU/ml for anti-tetanus and anti-diphtheria antibodies; 5 El.U/ml for antibodi…

MaleMicrobiology (medical)Vaccination scheduleEnzyme-Linked Immunosorbent AssayAntibodies ViralInjections IntramuscularRisk Assessmentcomplex mixturesConjugate vaccineGermanyConfidence IntervalsmedicineHumansHepatitis B VaccinesVaccines CombinedBacterial CapsulesDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleHaemophilus VaccinesProbabilityImmunity CellularReactogenicityGeneral Immunology and MicrobiologyTetanusbusiness.industryImmunogenicityDiphtheriaPolysaccharides BacterialVaccinationInfantGeneral MedicineHib Conjugate vaccinemedicine.diseaseAntibodies BacterialVirologyHexavalent combination; DTPa-HBV-IPV combination vaccine; Hib Conjugate vaccineVaccinationPoliovirus Vaccine InactivatedInfectious DiseasesItalyHib vaccineHexavalent combinationImmunologyFemalebusinessDTPa-HBV-IPV combination vaccineFollow-Up StudiesScandinavian Journal of Infectious Diseases
researchProduct

The NK Cell Response to Mouse Cytomegalovirus Infection Affects the Level and Kinetics of the Early CD8+ T-Cell Response

2012

ABSTRACT Natural killer (NK) cells and CD8 + T cells play a prominent role in the clearance of mouse cytomegalovirus (MCMV) infection. The role of NK cells in modulating the CD8 + T-cell response to MCMV infection is still the subject of intensive research. For analyzing the impact of NK cells on mounting of a CD8 + T-cell response and the contribution of these cells to virus control during the first days postinfection (p.i.), we used C57BL/6 mice in which NK cells are specifically activated through the Ly49H receptor engaged by the MCMV-encoded ligand m157. Our results indicate that the requirement for CD8 + T cells in early MCMV control inversely correlates with the engagement of Ly49H. W…

MaleMuromegalovirusImmunologyNK cellsCD8-Positive T-LymphocytesBiologym157MicrobiologyRodent DiseasesMice03 medical and health sciencesInterleukin 210302 clinical medicineVirologyAnimalsCytotoxic T cellmouse cytomegalovirus; NK cells; T-cell response; Ly49H; m157IL-2 receptor030304 developmental biologyMice Inbred BALB C0303 health sciencesJanus kinase 3ZAP70BIOMEDICINE AND HEALTHCARE. Basic Medical Sciences.Herpesviridae InfectionsNatural killer T cellMouse cytomegalovirus3. Good healthKiller Cells NaturalMice Inbred C57BLKineticsT-cell responseInsect ScienceImmunologyInterleukin 12CytokinesPathogenesis and ImmunityFemaleLy49HBIOMEDICINA I ZDRAVSTVO. Temeljne medicinske znanosti.CD8030215 immunology
researchProduct